These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3480933)

  • 41. [Presentation of 20 cases of lupus anticoagulant. Proposal for a methodology for its study].
    Mompel Sanjuán A; Abad Gosalbez A; García Pérez A; Marco Vera P
    Sangre (Barc); 1988 Aug; 33(4):306-9. PubMed ID: 3142061
    [No Abstract]   [Full Text] [Related]  

  • 42. Performance of Platelin LS and dilute Russell's viper venom for the screening of lupus anticoagulant in patients with venous thromboembolism.
    Morelli VM; Rodrigues CA; Noguti MA; Matos MF; da Silveira RC; Ribeiro AA; Lourenço DM
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):401-5. PubMed ID: 17581313
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Coagulation profile in systemic lupus erythematosus studies in 20 patients.
    Boey ML; Tsakok FH; Feng PH
    Singapore Med J; 1985; 26(4-5):361-4. PubMed ID: 4071090
    [No Abstract]   [Full Text] [Related]  

  • 44. Further studies on the hypercoagulable state of patients with Cushing's syndrome.
    Patrassi GM; Dal Bo Zanon R; Boscaro M; Martinelli S; Girolami A
    Thromb Haemost; 1985 Aug; 54(2):518-20. PubMed ID: 4082087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1 1/2-year-old girl: report of a case and review of the literature.
    Lee MT; Nardi MA; Hadzi-Nesic J; Karpatkin M
    Am J Hematol; 1996 Apr; 51(4):307-14. PubMed ID: 8602632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
    Payzin B; Adakan FY; Yalçin HC; Cetinkaya GS; Berkmen S; Eraslan S; Unsal B
    Turk J Gastroenterol; 2006 Sep; 17(3):183-90. PubMed ID: 16941251
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Acquired hemophilia caused by autoantibodies against factor VIII coagulation activity. Clinical, biological study and therapeutic indications. Experience based on a study of 9 cases].
    Liozon E; Delaire L; Turlure P; Jaccard A; Loustaud-Ratti V; Réméniéras L; Julia A; Gaillard S; Bordessoule D; Vidal E
    Ann Med Interne (Paris); 1997; 148(7):477-90. PubMed ID: 9538386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The lupus-anticoagulant: clinical and obstetric implications.
    Lubbe WF; Butler WS; Liggins GC
    N Z Med J; 1984 Jun; 97(758):398-402. PubMed ID: 6087227
    [No Abstract]   [Full Text] [Related]  

  • 49. Coagulation inhibitors.
    Corrigan JJ
    Am J Pediatr Hematol Oncol; 1980; 2(3):281-8. PubMed ID: 6776839
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Interference of factor VIII excess on the detection of lupus anticoagulants by the activated partial thromboplastin time].
    Guermazi S; Gorgi Y; Ayed K; Dellagi K
    Pathol Biol (Paris); 1997 Jan; 45(1):28-33. PubMed ID: 9097843
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
    Viveros ME; Cabiedes J; Reyes E; Cabral AR
    Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature.
    Vivaldi P; Rossetti G; Galli M; Finazzi G
    Haematologica; 1997; 82(3):345-7. PubMed ID: 9234588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Two different incubation times for the activated partial thromboplastin time (APTT): a new criterion for diagnosis of lupus anticoagulant.
    Robert A
    Thromb Haemost; 1994 Feb; 71(2):220-4. PubMed ID: 8191402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal.
    Bowyer A; Smith J; Woolley AM; Kitchen S; Hampton KK; Maclean RM; VAN Veen JJ; Makris M
    Int J Lab Hematol; 2011 Apr; 33(2):212-8. PubMed ID: 20880301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant.
    Mannucci PM; Canciani MT; Mari D; Meucci P
    Scand J Haematol; 1979 May; 22(5):423-32. PubMed ID: 472662
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lupus anticoagulant after measles.
    Muntean W; Petek W
    Eur J Pediatr; 1980 Aug; 134(2):135-8. PubMed ID: 6777164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Study of "lupus-type" anticoagulant using diluted Russell's viper venom time. Study of 16 patients].
    Pardo Vigo A; Oteyza JP; Blanco L; Correa MA; César J; Avello AG; Frade JG; Navarro JL
    Sangre (Barc); 1987; 32(2):231-5. PubMed ID: 3112970
    [No Abstract]   [Full Text] [Related]  

  • 59. Systemic lupus erythematosus circulating anticoagulant: report of a case.
    Haber-Cohen A; Burke JE
    J Oral Maxillofac Surg; 1988 Aug; 46(8):688-9. PubMed ID: 3135371
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Passovoy defect: further characterization of a hereditary hemorrhagic diathesis.
    Hougie C; Mc Pherson RA; Brown JE; Lakin-Thomas PL; Melaragno A; Aronson L; Baugh RF
    N Engl J Med; 1978 May; 298(19):1045-8. PubMed ID: 643012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.